* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:04:19 ON 03 APR 2009

=> index bioscience medicine
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 0.22 0.22

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS, CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 14:04:41 ON 03 APR 2009

71 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view
search error messages that display as 0* with SET DETAIL OFF.

=> S (MSS4 or PIP5K or (phosphotidylinositol (w) 4-phosphate-5-kinase))
13 FILE AGRICOLA
3 FILE AQUASCI
5 FILE BIOENG
137 FILE BIOSIS
9 FILE BIOTECHABS
9 FILE BIOTECHDS
39 FILE BIOTECHNO
9 FILE CABA
156 FILE CAPLUS
4 FILE CONFSCI
1 FILE DDFU
22 FILES SEARCHED...
242 FILE DGENE
16 FILE DISSABS
2 FILE DRUGU
1 FILE EMBAL
85 FILE EMBASE
87 FILE ESBIOBASE
168 FILE GENBANK
6 FILE IFIPAT
41 FILES SEARCHED...
48 FILE LIFESCI
107 FILE MEDLINE
2 FILE NTIS
13 FILE PASCAL
3 FILE PROMT
111 FILE SCISEARCH
29 FILE TOXCENTER
4 FILE USGENE
59 FILES SEARCHED...
99 FILE USPATFULL
2 FILE USPATOLD
17 FILE USPAT2
2 FILE WATER
9 FILE WPIDS
9 FILE WPINDEX
68 FILES SEARCHED...
1 FILE IPA

34 FILES HAVE ONE OR MORE ANSWERS, 71 FILES SEARCHED IN STNINDEX

L1 QUE (MSS4 OR PIP5K OR (PHOSPHOTIDYLINOSITOL (W) 4-PHOSPHATE-5-KINASE))

=> d rank
F1 242 DGENE
F2 168 GENBANK
F3 156 CAPLUS

F4 137 BIOSIS
F5 111 SCISEARCH
F6 107 MEDLINE
F7 99 USPATFULL
F8 87 ESBIOBASE
F9 85 EMBASE
F10 48 LIFESCI
F11 39 BIOTECHNO
F12 29 TOXCENTER
F13 17 USPAT2
F14 16 DISSABS
F15 13 AGRICOLA
F16 13 PASCAL
F17 9 BIOTECHABS
F18 9 BIOTECHDS
F19 9 CABA
F20 9 WPIDS
F21 9 WPINDEX
F22 6 IFIPAT
F23 5 BIOENG
F24 4 CONFSCI
F25 4 USGENE
F26 3 AQUASCI
F27 3 PROMT
F28 2 DRUGU
F29 2 NTIS
F30 2 USPATOLD
F31 2 WATER
F32 1 DDFU
F33 1 EMBAL
F34 1 IPA

=> file f3-f12, f20
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 2.72 2.94

FILE 'CAPLUS' ENTERED AT 14:06:54 ON 03 APR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 14:06:54 ON 03 APR 2009
Copyright (c) 2009 The Thomson Corporation

FILE 'SCISEARCH' ENTERED AT 14:06:54 ON 03 APR 2009
Copyright (c) 2009 The Thomson Corporation

FILE 'MEDLINE' ENTERED AT 14:06:54 ON 03 APR 2009

FILE 'USPATFULL' ENTERED AT 14:06:54 ON 03 APR 2009
CA INDEXING COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'ESBIOBASE' ENTERED AT 14:06:54 ON 03 APR 2009
COPYRIGHT (C) 2009 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'EMBASE' ENTERED AT 14:06:54 ON 03 APR 2009
Copyright (c) 2009 Elsevier B.V. All rights reserved.

FILE 'LIFESCI' ENTERED AT 14:06:54 ON 03 APR 2009
COPYRIGHT (C) 2009 Cambridge Scientific Abstracts (CSA)

FILE 'BIOTECHNO' ENTERED AT 14:06:54 ON 03 APR 2009
COPYRIGHT (C) 2009 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'TOXCENTER' ENTERED AT 14:06:54 ON 03 APR 2009
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 14:06:54 ON 03 APR 2009

=> S L1
L2 907 L1

=> S (inhibitor or inhibition or compound or agent) (s) L2
L3 65 (INHIBITOR OR INHIBITION OR COMPOUND OR AGENT) (S) L2

=> S contact? (s) L3
L4 2 CONTACT? (S) L3

=> S contact? and L3
L5 23 CONTACT? AND L3

=> S (growth or viability) and L5
L6 22 (GROWTH OR VIABILITY) AND L5

=> dup rem L6
PROCESSING COMPLETED FOR L6
L7 22 DUP REM L6 (0 DUPLICATES REMOVED)

=> D ibib abs L7 1-22

L7 ANSWER 1 OF 22 USPATFULL on STN
ACCESSION NUMBER: 2007:341045 USPATFULL <<LOGINID::20090403>>
TITLE: Ligands That Enhance Endogenous Compounds
INVENTOR(S): Tomlinson, Ian M., Great Shelford, UNITED KINGDOM

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2007029804I	AI	20071227
APPLICATION INFO.:	US 2005-667393	AI	20051110 (11)
	WO 2005-GB4319		20051110
			20070713 PCT 371 date

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2004-985847, filed on 10 Nov 2004, PENDING Continuation-in-part of Ser. No. WO 2005-GB4253, filed on 8 Oct 2004, UNKNOWN Continuation-in-part of Ser. No. WO 2005-GB5646, filed on 24 Dec 2003, UNKNOWN Continuation-in-part of Ser. No. WO 2005-GB2804, filed on 30 Jun 2003, UNKNOWN Continuation-in-part of Ser. No. WO 2005-GB3014, filed on 28 Jun 2002, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2002-30202	20021227
	GB 2003-27706	20031128

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HAMILTON, BROOK, SMITH & REYNOLDS, P.C., 530 VIRGINIA ROAD, P.O. BOX 9133, CONCORD, MA, 01742-9133, US
NUMBER OF CLAIMS: 98
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Page(s)
LINE COUNT: 6532
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to ligands that comprise a moiety (e.g., a dAb) that has a binding site with binding specificity for an endogenous target compound but do not substantially inhibit the activity of said endogenous target compound. Preferably, the ligand does not bind to the active site of an endogenous target compound. The invention relates to the use of such a ligand for the manufacture of a medicament for increasing the half-life, bioavailability, activity or amount of an endogenous target compound to which the ligand binds.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 2 OF 22 USPATFULL on STN
ACCESSION NUMBER: 2007:310522 USPATFULL <<LOGINID::20090403>>
TITLE: Methods for genetic control of plant pest infestation

and compositions thereof
INVENTOR(S): Boukharov, Andrey A., Wildwood, MO, UNITED STATES
Du, Zijin, Chesterfield, MO, UNITED STATES
Guo, Liang, St. Louis, MO, UNITED STATES
Kovalic, David K., Clayton, MO, UNITED STATES
Lu, Maolong, St. Louis, MO, UNITED STATES
McCarter, James P., St. Louis, MO, UNITED STATES
Miller, Nancy M., Fenton, MO, UNITED STATES
Vaudin, Mark, Cambridgeshire, UNITED KINGDOM
Williams, Deryck Jeremy, University City, MO, UNITED STATES
Wu, Wei, St. Louis, MO, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20070271630	A1	20071122
APPLICATION INFO.:	US 2006-360355	A1	20060223 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2005-655875P	20050224 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MONSANTO COMPANY, 800 N. LINDBERGH BLVD., ATTENTION: GAIL P. WUELLNER, IP PARALEGAL, (E2NA), ST. LOUIS, MO, 63167, US
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
LINE COUNT: 6802
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to controlling plant pest infestation, and particularly plant nematode infestation, by inhibiting one or more biological functions in the plant pest. The invention discloses methods and compositions for use in controlling plant pest infestation by providing one or more different recombinant double stranded RNA molecules in the diet of the pest in order to achieve a reduction in pest infestation through suppression of pest gene expression. The invention is also directed to methods for making transgenic plants that express the double stranded RNA molecules, to methods for detecting cells comprising the disclosed sequences, and to methods for detecting the disclosed sequences in biological samples.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 3 OF 22 USPATFULL on STN
ACCESSION NUMBER: 2007:88980 USPATFULL <<LOGINID::20090403>>
TITLE: BIOINFORMATICALLY DETECTABLE GROUP OF NOVEL VACCINIA REGULATORY GENES AND USES THEREOF
INVENTOR(S): Bentwich, Itzhak, 65 Kfar Daniel, Kfar Daniel, ISRAEL 73125
PATENT ASSIGNEE(S): ROSETTA GENOMICS, Rehovot, ISRAEL (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20070077553	A1	20070405
APPLICATION INFO.:	US 2003-605840	A1	20031030 (10)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: ROSETTA-GENOMICS, 10 PLAUT-STREET SCIENCE PARK, P.O. BOX 2061, REHOVOT, 76706, IL
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 17 Drawing Page(s)
LINE COUNT: 126036
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a group of novel viral RNA regulatory genes, here identified as "viral genomic address messenger genes" or "VGAM genes", and as "Viral genomic record" or "VGR genes". VGAM genes selectively inhibit translation of known host target genes, and are

believed to represent a novel pervasive viral attack mechanism. VGR genes encode an "operon"-like cluster of VGAM genes. VGAM and viral VGR genes may therefore be useful in diagnosing, preventing and treating viral disease. Several nucleic acid molecules are provided respectively encoding several VGAM genes, as are vectors and probes, both comprising the nucleic acid molecules, and methods and systems for detecting VGAM genes, and for counteracting their activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 4 OF 22 USPATFULL on STN
ACCESSION NUMBER: 2007:68596 USPATFULL <<LOGINID::20090403>>
TITLE: Reagents for the detection of protein phosphorylation in T-cell receptor signaling pathways
INVENTOR(S): Moritz, Albrecht, Salem, MA, UNITED STATES
Lee, Kimberly, Seattle, WA, UNITED STATES
Rush, John, Beverly, MA, UNITED STATES
Polakiewicz, Roberto, Lexington, MA, UNITED STATES
PATENT ASSIGNEE(S): CELL SIGNALING TECHNOLOGY, INC. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20070059845	A1	20070315
APPLICATION INFO.:	US 2006-503336	A1	20060811 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	WO 2004-US32511	20041004

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: JAMES GREGORY CULLEM, ESQ., INTELLECTUAL PROPERTY COUNSEL, CELL SIGNALING TECHNOLOGY, INC., 166B CUMMINGS CENTER, BEVERLY, MA, 01915, US
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1-42
NUMBER OF DRAWINGS: 9 Drawing Page(s)
LINE COUNT: 2832
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention discloses 95 novel phosphorylation sites identified in signal transduction proteins and pathways downstream of the T-cell receptor, and provides phosphorylation-site specific antibodies and heavy-isotope labeled peptides (AQUA peptides) for the selective detection and quantification of these phosphorylated sites/proteins, as well as methods of using the reagents for such purpose. Among the phosphorylation sites identified are sites occurring in the following protein types: Actin Binding proteins, Adaptor/Scaffold proteins, Adhesion proteins, Calcium-binding proteins, Cell Cycle Regulation or Channel proteins, Chaperones, Cofactor proteins, Cytoskeletal proteins, DNA Binding proteins, G protein or GTPase Activating proteins, Ligases, Lipid Kinases and Binding proteins, Oxidoreductases, Protein Kinases, Protein Phosphatases, Receptor proteins, RNA Binding proteins, Transcription Factor/Initiation Complex proteins, Transcription Coactivator/Corepressor proteins, Translation Initiation Complex proteins, Ubiquitin Conjugating System proteins, and Vesicle proteins.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 5 OF 22 USPATFULL on STN
ACCESSION NUMBER: 2007:23624 USPATFULL <<LOGINID::20090403>>
TITLE: Differentially expressed genes in large granular lymphocyte leukemia
INVENTOR(S): Loughran, Thomas P. JR., Hummelstown, PA, UNITED STATES
Kothapalli, Ravi, Wesley Chapel, FL, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20070020666	A1	20070125
APPLICATION INFO.:	US 2006-476407	A1	20060628 (11)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2004-766157, filed on 28 Jan 2004, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-319910P	20030128 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SALIWANCHIK LLOYD & SALIWANCHIK, A PROFESSIONAL ASSOCIATION, PO BOX 142950, GAINESVILLE, FL, 32614-2950, US
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 13 Drawing Page(s)
LINE COUNT: 2239
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The subject invention concerns gene sequences and the use thereof as markers for large granular lymphocyte (LGL) leukemia. The gene sequences of the invention are differentially expressed in LGL. Another aspect of the invention pertains to therapeutic compositions directed to gene expression and gene products of differentially expressed genes in LGL. The invention also concerns methods for screening and identifying compositions that may be of therapeutic benefit to patients having LGL leukemia and/or autoimmune disorders. In addition, because a large fraction of patients with T-LGL leukemia also have rheumatoid arthritis, these differentially expressed genes also represent novel targets for the diagnosis, prevention or treatment of rheumatoid arthritis and other autoimmune diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 6 OF 22 USPATFULL on STN
ACCESSION NUMBER: 2006:181854 USPATFULL <<LOGINID::20090403>>
TITLE: Novel compositions and methods in cancer
INVENTOR(S): Morris, David W, Davis, CA, UNITED STATES
Malandro, Marc S, Davis, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20060154250	A1	20060713
APPLICATION INFO.:	US 2003-539228	A1	20031215 (10)
	WO 2003-US40081		20031215
			20051028 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-10322281	20021217

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SAGRES DISCOVERY INC., INTELLECTUAL PROPERTY - R440, P.O. BOX 8097, EMERYVILLE, CA, 94662-8097, US
NUMBER OF CLAIMS: 77
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Page(s)
LINE COUNT: 7665
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to novel sequences for use in detection, diagnosis and treatment of cancers, especially lymphomas. The invention provides cancer-associated (CA) polynucleotide sequences whose expression is associated with cancer. The present invention provides CA polypeptides associated with cancer and provides diagnostic compositions and methods for the detection of cancer. The present invention provides monoclonal and polyclonal antibodies specific for the CA polypeptides. The present invention also provides diagnostic tools and therapeutic compositions and methods for screening, prevention and treatment of cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 7 OF 22 USPATFULL on STN
ACCESSION NUMBER: 2006:166421 USPATFULL <<LOGINID::20090403>>
TITLE: Mss4 as an antifungal target

INVENTOR(S): Haydon, David John, Oxford, UNITED KINGDOM

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20060140926	A1	20060629
APPLICATION INFO.:	US 2003-537756	A1	20031209 (10)
	WO 2003-GB5376		20031209
			20051025 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2002-28706	20021209

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: KLAUBER & JACKSON, 411 HACKENSACK AVENUE, HACKENSACK, NJ, 07601, US
NUMBER OF CLAIMS: 22
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Page(s)
LINE COUNT: 836
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides 1-phosphotidylinositol-4-phosphate 5-kinase (MSS4) as a novel antifungal target, screening methods for MSS4 inhibitors and their use as antifungal compounds, pharmaceutical compositions containing them and their use in medicine.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 8 OF 22 USPATFULL on STN
ACCESSION NUMBER: 2005:261277 USPATFULL <<LOGINID::20090403>>
TITLE: Cell cycle progression proteins
INVENTOR(S): Glover, David M., Cambridge, UNITED KINGDOM
Bell, Graham, Dundee, UNITED KINGDOM
Frenz, Lisa M., Cambridgeshire, UNITED KINGDOM
Midgley, Carol, Cambridgeshire, UNITED KINGDOM
PATENT ASSIGNEE(S): Polgen (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20050227301	A1	20051013
APPLICATION INFO.:	US 2003-745237	A1	20031223 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-468402P	20030506 (60)
	US 2003-439123P	20030110 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: PALMER & DODGE, LLP, KATHLEEN M. WILLIAMS, 111 HUNTINGTON AVENUE, BOSTON, MA, 02199, US
NUMBER OF CLAIMS: 1
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 295 Drawing Page(s)
LINE COUNT: 4281
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention describes human genes involved in cell cycle progression, including mitosis and meiosis. The invention also relates to the use of these "cell cycle progression" genes and proteins in the modulation of cell cycle progression in cells and methods for identifying modulators of these genes or proteins and hence modulators of mitosis and meiosis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 9 OF 22 USPATFULL on STN
ACCESSION NUMBER: 2005:204474 USPATFULL <<LOGINID::20090403>>
TITLE: Identification and characterization of plant genes
INVENTOR(S): Zhu, Tong, Research Triangle Park, NC, UNITED STATES
Chen, Wengiong, San Diego, CA, UNITED STATES
Briggs, Steven P., Del Mar, CA, UNITED STATES
Cooper, Bret, La Jolla, CA, UNITED STATES

Golf, Stephen A., Research Triangle Park, NC, UNITED STATES
Moughamer, Todd, Research Triangle Park, NC, UNITED STATES
GlazeBrook, Jane, San Diego, CA, UNITED STATES
Katagiri, Fumiaki, St. Paul, CA, UNITED STATES
Kreps, Joel, San Diego, CA, UNITED STATES
Provart, Nicolas J., Toronto, CANADA
Ricke, Darrell, Research Triangle Park, NC, UNITED STATES
PATENT ASSIGNEE(S): SYNGENTA PARTICIPATIONS AG (U.S. corporation)

NUMBER	KIND	DATE
PATENT INFORMATION:	US 20050177901	A1 20050811
APPLICATION INFO.:	US 2003-481032	A1 20020621 (10)
	WO 2002-IB2450	20020621

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: JENKINS, WILSON & TAYLOR, P. A., 3100 TOWER BLVD, SUITE 1400, DURHAM, NC, 27707, US
NUMBER OF CLAIMS: 60
EXEMPLARY CLAIM: 1
LINE COUNT: 9816
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention discloses a set of genes the expression products of which are up-regulated during the grain filling process in rice and active in different metabolic pathways involved in nutrient partitioning. The invention also discloses the use of said genes to modify the compositional and nutritional characteristics of the plant grain.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 10 OF 22 USPATFULL on STN
ACCESSION NUMBER: 2005:117724 USPATFULL <<LOGINID::20090403>>
TITLE: Albumin fusion proteins
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc. (U.S. corporation)

NUMBER	KIND	DATE
PATENT INFORMATION:	US 20050100991	A1 20050512
APPLICATION INFO.:	US 2004-932104	A1 20040902 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2001-833118, filed on 12 Apr 2001, PENDING	

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, LLP, 901 NEW YORK AVENUE, NW, WASHINGTON, DC, 20001-4413, US
NUMBER OF CLAIMS: 33
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 20 Drawing Page(s)
LINE COUNT: 15444
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 11 OF 22 USPATFULL on STN
ACCESSION NUMBER: 2005:50706 USPATFULL <<LOGINID::20090403>>

TITLE: Acyl-nucleotide probes and methods of their synthesis and use in proteomic analysis
INVENTOR(S): Campbell, David Alan, San Diego, CA, UNITED STATES
Liyanage, Marek, Carlsbad, CA, UNITED STATES
Szardenings, Anna Katrin, San Diego, CA, UNITED STATES
Wu, Min, San Diego, CA, UNITED STATES
PATENT ASSIGNEE(S): ActivX Biosciences, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20050043507	A1	20050224
	US 7365178	B2	20080429
APPLICATION INFO.:	US 2004-817454	A1	20040401 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-459797P	20030401 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: FOLEY & LARDNER, P.O. BOX 80278, SAN DIEGO, CA, 92138-0278
NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Page(s)
LINE COUNT: 5172
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides tagged acyl phosphate probes ("TAPPs"), and methods of their preparation and use. The subject methods and compositions can provide enhanced simplicity and accuracy in identifying changes in the presence, amount, or activity of target proteins in a complex protein mixture, preferably nucleotide binding proteins using nucleotide binding protein-directed TAPPs. The profiling methods described herein can have a number of steps leading to the identification of target nucleotide binding protein(s) in a complex protein mixture.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 12 OF 22 USPATFULL on STN
ACCESSION NUMBER: 2004:314486 USPATFULL <<LOGINID::20090403>>
TITLE: Differentially expressed genes in large granular lymphocyte leukemia
INVENTOR(S): Loughran, Thomas P., JR., Hummelstown, PA, UNITED STATES
Kothapalli, Ravi, Wesley Chapel, FL, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20040248158	A1	20041209
APPLICATION INFO.:	US 2004-766157	A1	20040128 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-319910P	20030128 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SALIWANCHIK LLOYD & SALIWANCHIK, A PROFESSIONAL ASSOCIATION, PO BOX 142950, GAINESVILLE, FL, 32614-2950
NUMBER OF CLAIMS: 18
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 13 Drawing Page(s)
LINE COUNT: 2207
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The subject invention concerns gene sequences and the use thereof as markers for large granular lymphocyte (LGL) leukemia. The gene sequences of the invention are differentially expressed in LGL. Another aspect of the invention pertains to therapeutic compositions directed to gene expression and gene products of differentially expressed genes in LGL. The invention also concerns methods for screening and identifying compositions that may be of therapeutic benefit to patients having LGL

leukemia and/or autoimmune disorders. In addition, because a large fraction of patients with T-LGL leukemia also have rheumatoid arthritis, these differentially expressed genes also represent novel targets for the diagnosis, prevention or treatment of rheumatoid arthritis and other autoimmune diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 13 OF 22 USPATFULL on STN
ACCESSION NUMBER: 2004:20717 USPATFULL <<LOGINID::20090403>>
TITLE: Rice promoters for regulation of plant expression
INVENTOR(S): Budworth, Paul, San Diego, CA, UNITED STATES
Moughamer, Todd, San Diego, CA, UNITED STATES
Briggs, Steven P., Del Mar, CA, UNITED STATES
Cooper, Bret, La Jolla, CA, UNITED STATES
Glazebrook, Jane, San Diego, CA, UNITED STATES
Goff, Stephen Arthur, Encinitas, CA, UNITED STATES
Katagiri, Fumiaki, San Diego, CA, UNITED STATES
Kreps, Joel, Carlsbad, CA, UNITED STATES
Provart, Nicholas, Toronto, CANADA
Ricke, Darrell, San Diego, CA, UNITED STATES
Zhu, Tong, San Diego, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20040016025	A1	20040122
APPLICATION INFO.:	US 2002-260238	A1	20020926 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-325448P	20010926 (60)
	US 2001-325277P	20010926 (60)
	US 2002-370620P	20020404 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: James E. Butler, Torrey Mesa Research Institute, 3115 Merryfield Row, San Diego, CA, 92121
NUMBER OF CLAIMS: 77
EXEMPLARY CLAIM: 1
LINE COUNT: 18818
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides a method to identify a plurality of plant promoters having a particular characteristic as well as the sequence of promoters having one of those characteristics.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 14 OF 22 USPATFULL on STN
ACCESSION NUMBER: 2004:7329 USPATFULL <<LOGINID::20090403>>
TITLE: Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
INVENTOR(S): Mack, David H., Menlo Park, CA, UNITED STATES
Gish, Kurt C., San Francisco, CA, UNITED STATES
PATENT ASSIGNEE(S): Eos Biotechnology, Inc., South San Francisco, CA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20040005563	A1	20040108
	US 7189507	B2	20070313
APPLICATION INFO.:	US 2002-173999	A1	20020617 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-372246P	20020412 (60)
	US 2001-350666P	20011113 (60)
	US 2001-315287P	20010827 (60)
	US 2001-299234P	20010618 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 32540
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Described herein are genes whose expression are up-regulated or down-regulated in ovarian cancer. Related methods and compositions that can be used for diagnosis and treatment of ovarian cancer are disclosed. Also described herein are methods that can be used to identify modulators of ovarian cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 15 OF 22 USPATFULL on STN
ACCESSION NUMBER: 2004:141216 USPATFULL <<LOGINID::20090403>>
TITLE: Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics
INVENTOR(S): Weinstock, Keith G., Westborough, MA, United States
Bush, David, Somerville, MA, United States
PATENT ASSIGNEE(S): Genome Therapeutics Corporation, Waltham, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6747137	B1	20040608
APPLICATION INFO.:	US 1999-248796		19990212 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-96409P	19980813 (60)
	US 1998-74725P	19980213 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Marschel, Ardin H.
LEGAL REPRESENTATIVE: Genome Therapeutics Corporation
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 36816
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention provides isolated polypeptide and nucleic acid sequences derived from Candida albicans that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting from fungal infection.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 16 OF 22 USPATFULL on STN
ACCESSION NUMBER: 2004:97416 USPATFULL <<LOGINID::20090403>>
TITLE: Nucleic acid molecule and encoded protein associated with sterol synthesis and metabolism
INVENTOR(S): Karunanandaa, Balasulojini, Creve Coeur, MO, United States
Yu, Jaehyuk, Madison, WI, United States
Kishore, Ganesh, Creve Coeur, MO, United States
PATENT ASSIGNEE(S): Monsanto Technology LLC, St. Louis, MO, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6723837	B1	20040420
APPLICATION INFO.:	US 2000-614221		20000711 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-142981P	19990712 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Fox, David T.
ASSISTANT EXAMINER: Kallis, Russell
LEGAL REPRESENTATIVE: McBride, Thomas P., Arnold & Porter LLP
NUMBER OF CLAIMS: 2
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 5838
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to the field of biotechnology, particularly as it pertains to a nucleic acid molecule encoding a protein associated with sterol and phytosterol synthesis and metabolism. The invention also relates to methods of detection using the nucleic acid molecule, or the encoded protein as a probe or in a microarray.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 17 OF 22 WPIDS COPYRIGHT 2009 THOMSON REUTERS on STN
ACCESSION NUMBER: 2004-468882 [44] WPIDS
DOC. NO. CPI: C2004-175782 [44]
TITLE: Screening or testing candidate anti-fungal compounds that impair 1- ***phosphotidylinositol*** - ***4*** - ***phosphate*** ***5*** - ***kinase*** enzyme (***MSS4***) function, by ***contacting*** ***MSS4*** with candidate compounds, and determining interaction of ***compound*** with ***MSS4***
DERWENT CLASS: B04; C07; D16
INVENTOR: HAYDON D J
PATENT ASSIGNEE: (OXFO-N) OXFORD GLYCOSCIENCES UK LTD; (HAYD-I) HAYDON D J
COUNTRY COUNT: 106

PATENT INFO ABBR.:

PATENT NO	KIND DATE	WEEK	LA	PG	MAIN IPC
WO 2004053150	A1 20040624	(200444)*	EN	23	[3]
AU 2003290244	A1 20040630	(200472)	EN		
EP 1573049	A1 20050914	(200560)	EN		
US 20060140926	A1 20060629	(200643)	EN		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2004053150	A1	WO 2003-GB5376	20031209
AU 2003290244	A1	AU 2003-290244	20031209
EP 1573049	A1	EP 2003-782609	20031209
EP 1573049	A1	WO 2003-GB5376	20031209
US 20060140926	A1	WO 2003-GB5376	20031209
US 20060140926	A1	US 2005-537756	20051025

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 2003290244	A1 Based on	WO 2004053150 A
EP 1573049	A1 Based on	WO 2004053150 A

PRIORITY APPLN. INFO: GB 2002-28706 20021209
AN 2004-468882 [44] WPIDS
AB WO 2004053150 A1 UPAB: 20060121
NOVELTY - Screening or testing (M1) candidate anti-fungal compounds that impair 1- ***phosphotidylinositol*** - ***4*** - ***phosphate*** ***5*** - ***kinase*** enzyme (***MSS4***) function, involves providing fungal ***MSS4*** , providing one or more candidate compounds, ***contacting*** ***MSS4*** with one or more candidate compounds, and determining the interaction of the candidate ***compound*** with ***MSS4*** .
DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for:

(1) a modified eukaryotic cell(s) (I) expressing fungal MSS4 under the control of a heterologous promoter;

(2) a ***compound*** (C1) identified by (M1), which impairs ***MSS4*** function for use as an antifungal ***compound*** ;

(3) a pharmaceutical composition (PC) comprising ***MSS4*** ***inhibitor*** and a carrier;

(4) Candida or Aspergillus MSS4 as a specific target for antifungal compounds; and

(5) use of ***MSS4*** ***inhibitor*** (II) for manufacturing a medicament for treating fungal infections and treating fungal infections in a subject who is immunosuppressed.

ACTIVITY - Fungicide.

The ability of ***MSS4*** ***inhibitor*** to control the systemic infection caused by C.albicans was tested as follows. Animals were fed food and water ad libitum throughout the course of experiment. In the DOX-treated group (+DOX), mice were administered with DOX (2 mg/ml) dissolved in 5% sucrose solution as drinking water from 2 days before the inoculation of C.albicans cells. The mice were known to drink approximately 5 ml of sucrose solution every day. Under this regimen, the concentration of DOX in serum, liver and kidney were maintained at more than 2 mg/ml of serum, 8 mg/g of liver, and 10 mg/g of kidney, respectively (Nakayama, H., et al., 1998, Microbiology 144:2407-2415). Percent survival was followed over 28 days with daily body weight monitoring. Differences between the effects of C.albicans with the ***MSS4*** gene active (-DOX) or repressed (+DOX) in vivo were monitored by mouse survival, kidney burdens of viable fungi, and changes in body weight relative to baseline. Results showed that kidney counts (colony forming unit counts per gram of kidney tissue) for the (+DOX) group was significantly reduced compared to the control group (-DOX) and these mice also maintained their weight throughout the course of the study.

MECHANISM OF ACTION - ***Inhibitor*** of ***MSS4*** (claimed).

USE - (M1) is useful for screening or testing candidate anti-fungal compounds that impair ***MSS4*** function. (I) is useful for screening or testing candidate anti-fungal ***compound*** that impair ***MSS4*** function which involves providing fungal ***MSS4*** in (I), providing one or more candidate compounds, ***contacting*** (I) with the one or more candidate compounds, and determining the interaction of the candidate ***compound*** with ***MSS4*** by assessing the effect on ***growth*** or ***viability*** of the cells (all claimed). PC is useful for treating fungal infections caused by Candida and Aspergillus species, preferably C.albicans, and A.flavus or A.fumigatus.

ADVANTAGE - (C1) impairs fungal MSS4 function to a greater extent than host MSS4 function (claimed).

DESCRIPTION OF DRAWINGS - The figure shows survival rate of mice infected with Candida albicans strain treated with MSS4 gene.

L7 ANSWER 18 OF 22 USPATFULL on STN
ACCESSION NUMBER: 2003:312278 USPATFULL <<LOGINID::20090403>>
TITLE: Albumin fusion proteins
INVENTOR(S): Rosen, Craig A., Laytonsville, MD, UNITED STATES
Haseltine, William A., Washington, DC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20030219875	A1	20031127
	US 6905688	B2	20050614
APPLICATION INFO.:	US 2001-833118	A1	20010412 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256931P	20001221 (60)
	US 2000-199384P	20000425 (60)
	US 2000-229358P	20000412 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: HUMAN GENOME SCIENCES INC, 9410 KEY WEST AVENUE, ROCKVILLE, MD, 20850
NUMBER OF CLAIMS: 29

EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 18 Drawing Page(s)
LINE COUNT: 15415
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention encompasses albumin fusion proteins. Nucleic acid molecules encoding the albumin fusion proteins of the invention are also encompassed by the invention, as are vectors containing these nucleic acids, host cells transformed with these nucleic acids vectors, and methods of making the albumin fusion proteins of the invention and using these nucleic acids, vectors, and/or host cells. Additionally the present invention encompasses pharmaceutical compositions comprising albumin fusion proteins and methods of treating, preventing, or ameliorating diseases, disordrs or conditions using albumin fusion proteins of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 19 OF 22 USPATFULL on STN
ACCESSION NUMBER: 2003:200818 USPATFULL <<LOGINID::20090403>>
TITLE: Identification and use of molecules implicated in pain
INVENTOR(S): Brookesbank, Robert Alan, Cambridge, UNITED KINGDOM
Dixon, Alistair Kerr, Cambridge, UNITED KINGDOM
Lee, Kevin, Cambridge, UNITED KINGDOM
Pinnock, Robert Denham, Ann Arbor, MI, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20030138803	A1	20030724
APPLICATION INFO.:	US 2002-205219	A1	20020724 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2002-2910	20020207
	GB 2001-18354	20010727

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Mehdi Ganjeizadeh, Ph.D., Warner-Lambert Company, 2800 Plymouth Road, Ann Arbor, MI, 48105
NUMBER OF CLAIMS: 36
EXEMPLARY CLAIM: 1
LINE COUNT: 2626
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to the use of:

(a) an isolated gene sequence that is up regulated in the spinal cord in response to streptozocin-induced diabetes;

(b) an isolated gene sequence comprising a nucleic acid sequence of Tables I to X.

(c) an isolated gene sequence having at least 80% sequence identity with a nucleic acid sequence of Tables I to X;

(d) an isolated nucleic acid sequence that is hybridizable to any of the gene sequences according to (a), (b) or (c) under stringent hybridisation conditions;

(e) a recombinant vector comprising a gene sequence or nucleic acid sequence according to any one of (a) to (d);

(f) a host cell containing the vector according to (e);

(g) a non-human animal having in its genome an introduced gene sequence or nucleic acid sequence or a removed or down-regulated gene sequence or nucleic acid sequence according to any one of (a) to (d);

(h) an isolated polypeptide comprising an amino acid sequence at least 90% identical to an amino acid sequence encoded by a nucleotide sequence according to any one of (a) to (d), or a polypeptide variant thereof with sequential amino acid deletions from the C terminus and/or the

N-terminus; or

(i) an isolated polypeptide encoded by a nucleotide sequence according to any one of (a) to (d); or

(k) an isolated antibody that binds specifically to a polypeptide according to (h) or (i);

in the screening of compounds for the treatment of pain, or for the diagnosis of pain.

The invention also relates to the use of naturally occurring compounds such as peptide ligands of the expression products of the above gene sequences and their associated signal transduction pathways for use in the treatment of pain.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 20 OF 22 USPATFULL on STN
ACCESSION NUMBER: 2003:120026 USPATFULL <<LOGINID::20090403>>
TITLE: Identification of modulatory molecules using inducible promoters
INVENTOR(S): Brown, Steven J., San Diego, CA, UNITED STATES
Dunnington, Damien J., San Diego, CA, UNITED STATES
Clark, Imran, San Diego, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20030082511	A1	20030501
APPLICATION INFO.:	US 2001-965201	A1	20010925 (9)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: David B. Waller & Associates, 5677 Oberlin Drive, Suit 214, San Diego, CA, 92121
NUMBER OF CLAIMS: 52
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Page(s)
LINE COUNT: 5526
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Methods for identifying an ion channel modulator, a target membrane receptor modulator molecule, and other modulatory molecules are disclosed, as well as cells and vectors for use in those methods. A polynucleotide encoding target is provided in a cell under control of an inducible promoter, and candidate modulatory molecules are ***contacted*** with the cell after induction of the promoter to ascertain whether a change in a measurable physiological parameter occurs as a result of the candidate modulatory molecule.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 21 OF 22 USPATFULL on STN
ACCESSION NUMBER: 2003:17949 USPATFULL <<LOGINID::20090403>>
TITLE: Upregulation of type III endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization
INVENTOR(S): Liao, James K., Weston, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20030013703	A1	20030116
	US 6696480	B2	20040224
APPLICATION INFO.:	US 2002-144669	A1	20020513 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 1998-115387, filed on 14 Jul 1998, GRANTED, Pat. No. US 6423751
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Konstantinos Andrikopoulos, Wolf, Greenfield & Sacks P.C., 600 Atlantic Ave., Boston, MA, 02110
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 6 Drawing Page(s)
LINE COUNT: 2375
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A use for agents that disrupt actin cytoskeletal organization is provided. In the instant invention, agents that disrupt actin cytoskeletal organization are found to upregulate endothelial cell Nitric Oxide Synthase activity. As a result, agents that disrupt actin cytoskeletal organization are useful in treating or preventing conditions that result from the abnormally low expression and/or activity of endothelial cell Nitric Oxide Synthase. Such conditions include hypoxia-induced conditions. Subjects thought to benefit mostly from such treatments include nonhyperlipidemics and nonhypercholesterolemics, but not necessarily exclude hyperlipidemics and hypercholesterolemics.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 22 OF 22 USPATFULL on STN
ACCESSION NUMBER: 2002:157674 USPATFULL <<LOGINID::20090403>>
TITLE: UPREGULATION OF TYPE III ENDOTHELIAL CELL NITRIC OXIDE SYNTHASE BY AGENTS THAT DISRUPT ACTIN CYTOSKELETAL ORGANIZATION
INVENTOR(S): LIAO, JAMES K., WESTON, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002008228I	AI	20020627
	US 6423751	B2	20020723
APPLICATION INFO.:	US 1998-115387	AI	19980714 (9)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: EDWARD R GATES, WOLF GREENFIELD & SACKS, 600 ATLANNTIC AVENUE, BOSTON, MA, 02210
NUMBER OF CLAIMS: 77
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Page(s)
LINE COUNT: 2598
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A use for agents that disrupt actin cytoskeletal organization is provided. In the instant invention, agents that disrupt actin cytoskeletal organization are found to upregulate endothelial cell Nitric Oxide Synthase activity. As a result, agents that disrupt actin cytoskeletal organization are useful in treating or preventing conditions that result from the abnormally low expression and/or activity of endothelial cell Nitric Oxide Synthase. Such conditions include pulmonary hypertension, ischemic stroke, impotence, heart failure, hypoxia-induced conditions, insulin deficiency, progressive renal disease, gastric or esophageal motility syndrome, etc. Subjects thought to benefit mostly from such treatments include nonhyperlipidemics and nonhypercholesterolemics, but not necessarily exclude hyperlipidemics and hypercholesterolemics.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> D his

(FILE 'HOME' ENTERED AT 14:04:19 ON 03 APR 2009)

INDEX 'ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, ANTE, AQUALINE, AQUASCI, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CAPLUS, CEABA-VTB, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE, ...' ENTERED AT 14:04:41 ON 03 APR 2009

SEA (MSS4 OR PIP5K OR (PHOSPHOTIDYLINOSITOL (W) 4-PHOSPHATE-5-K

13	FILE AGRICOLA
3	FILE AQUASCI
5	FILE BIOENG
137	FILE BIOSIS
9	FILE BIOTECHABS

```
            9  FILE BIOTECHDS
           39  FILE BIOTECHNO
            9  FILE CABA
          156  FILE CAPLUS
            4  FILE CONFSCI
            1  FILE DDFU
          242  FILE DGENE
           16  FILE DISSABS
            2  FILE DRUGU
            1  FILE EMBAL
           85  FILE EMBASE
           87  FILE ESBIOBASE
          168  FILE GENBANK
            6  FILE IFIPAT
           48  FILE LIFESCI
          107  FILE MEDLINE
            2  FILE NTIS
           13  FILE PASCAL
            3  FILE PROMT
          111  FILE SCISEARCH
           29  FILE TOXCENTER
            4  FILE USGENE
           99  FILE USPATFULL
            2  FILE USPATOLD
           17  FILE USPAT2
            2  FILE WATER
            9  FILE WPIDS
            9  FILE WPINDEX
            1  FILE IPA
L1            QUE (MSS4 OR PIP5K OR (PHOSPHOTIDYLINOSITOL (W) 4-PHOSPHATE-5-K
              ----------

     FILE 'CAPLUS, BIOSIS, SCISEARCH, MEDLINE, USPATFULL, ESBIOBASE, EMBASE,
     LIFESCI, BIOTECHNO, TOXCENTER, WPIDS' ENTERED AT 14:06:54 ON 03 APR 2009
L2          907 S L1
L3           65 S (INHIBITOR OR INHIBITION OR COMPOUND OR AGENT) (S) L2
L4            2 S CONTACT? (S) L3
L5           23 S CONTACT? AND L3
L6           22 S (GROWTH OR VIABILITY) AND L5
L7           22 DUP REM L6 (0 DUPLICATES REMOVED)

=> log Y
COST IN U.S. DOLLARS                      SINCE FILE      TOTAL
                                     ENTRY    SESSION
FULL ESTIMATED COST                      105.09     108.03

STN INTERNATIONAL LOGOFF AT 14:09:18 ON 03 APR 2009
```